

Jee Hoon Roh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3948329/publications.pdf>

Version: 2024-02-01

98
papers

4,282
citations

279798

23
h-index

114465

63
g-index

115
all docs

115
docs citations

115
times ranked

7354
citing authors

#	ARTICLE	IF	CITATIONS
1	Neuronal activity regulates the regional vulnerability to amyloid- β^2 deposition. <i>Nature Neuroscience</i> , 2011, 14, 750-756.	14.8	744
2	Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. <i>Nature Medicine</i> , 2019, 25, 277-283.	30.7	610
3	Disruption of the Sleep-Wake Cycle and Diurnal Fluctuation of β^2 -Amyloid in Mice with Alzheimer's Disease Pathology. <i>Science Translational Medicine</i> , 2012, 4, 150ra122.	12.4	454
4	Circadian clock proteins regulate neuronal redox homeostasis and neurodegeneration. <i>Journal of Clinical Investigation</i> , 2013, 123, 5389-5400.	8.2	393
5	A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. <i>Nature Medicine</i> , 2020, 26, 398-407.	30.7	351
6	An atlas of cortical circular RNA expression in Alzheimer disease brains demonstrates clinical and pathological associations. <i>Nature Neuroscience</i> , 2019, 22, 1903-1912.	14.8	242
7	Potential role of orexin and sleep modulation in the pathogenesis of Alzheimer's disease. <i>Journal of Experimental Medicine</i> , 2014, 211, 2487-2496.	8.5	189
8	Translational profiling of hypocretin neurons identifies candidate molecules for sleep regulation. <i>Genes and Development</i> , 2013, 27, 565-578.	5.9	87
9	Recent Updates on Subcortical Ischemic Vascular Dementia. <i>Journal of Stroke</i> , 2014, 16, 18.	3.2	78
10	Enhancing surface functionality of reduced graphene oxide biosensors by oxygen plasma treatment for Alzheimer's disease diagnosis. <i>Biosensors and Bioelectronics</i> , 2017, 92, 610-617.	10.1	70
11	Volume reduction in subcortical regions according to severity of Alzheimer's disease. <i>Journal of Neurology</i> , 2011, 258, 1013-1020.	3.6	66
12	Region and frequency specific changes of spectral power in Alzheimer's disease and mild cognitive impairment. <i>Clinical Neurophysiology</i> , 2011, 122, 2169-2176.	1.5	63
13	Prediction of Alzheimer's disease pathophysiology based on cortical thickness patterns. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 2, 58-67.	2.4	58
14	Neural substrates of cognitive reserve in Alzheimer's disease spectrum and normal aging. <i>NeuroImage</i> , 2019, 186, 690-702.	4.2	58
15	Cortical asymmetries in normal, mild cognitive impairment, and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2012, 33, 1959-1966.	3.1	57
16	The relationship of pain and health-related quality of life in Korean patients with Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2009, 119, 397-403.	2.1	43
17	Accelerated functional brain aging in pre-clinical familial Alzheimer's disease. <i>Nature Communications</i> , 2021, 12, 5346.	12.8	43
18	The clinical feasibility of deep learning-based classification of amyloid PET images in visually equivocal cases. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 332-341.	6.4	37

#	ARTICLE	IF	CITATIONS
19	Development and Validation of a Deep Learning-Based Automatic Brain Segmentation and Classification Algorithm for Alzheimer Disease Using 3D T1-Weighted Volumetric Images. <i>American Journal of Neuroradiology</i> , 2020, 41, 2227-2234.	2.4	37
20	Cardiovascular Risk Factors Cause Cortical Thinning in Cognitively Impaired Patients. <i>Alzheimer Disease and Associated Disorders</i> , 2012, 26, 106-112.	1.3	36
21	Comparative analyses of plasma amyloid- β^2 levels in heterogeneous and monomerized states by interdigitated microelectrode sensor system. <i>Science Advances</i> , 2019, 5, eaav1388.	10.3	34
22	Amyloid and Tau Pathology Associations With Personality Traits, Neuropsychiatric Symptoms, and Cognitive Lifestyle in the Preclinical Phases of Sporadic and Autosomal Dominant Alzheimer's Disease. <i>Biological Psychiatry</i> , 2021, 89, 776-785.	1.3	30
23	Spectral-based automatic labeling and refining of human cortical sulcal curves using expert-provided examples. <i>NeuroImage</i> , 2010, 52, 142-157.	4.2	29
24	iPSC Modeling of Presenilin1 Mutation in Alzheimer's Disease with Cerebellar Ataxia. <i>Experimental Neurobiology</i> , 2018, 27, 350-364.	1.6	25
25	Analysis of frontotemporal dementia, amyotrophic lateral sclerosis, and other dementia-related genes in 107 Korean patients with frontotemporal dementia. <i>Neurobiology of Aging</i> , 2018, 72, 186.e1-186.e7.	3.1	25
26	Reversible Injury of Internal Capsule and Splenium in a Patient with Transient Hypoglycemic Hemiparesis. <i>Cerebrovascular Diseases</i> , 2006, 22, 282-283.	1.7	24
27	The Efficacy of Cognitive Intervention Programs for Mild Cognitive Impairment: A Systematic Review.. <i>Current Alzheimer Research</i> , 2015, 12, 527-542.	1.4	21
28	Ultrasonographic findings of shoulder disorders in patients with Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 1772-1776.	3.9	20
29	Differences in gray and white matter 18F-THK5351 uptake between behavioral-variant frontotemporal dementia and other dementias. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 357-366.	6.4	19
30	Comparison of Amyloid β^2 and Tau Spread Models in Alzheimer's Disease. <i>Cerebral Cortex</i> , 2019, 29, 4291-4302.	2.9	19
31	Cortical Laminar Necrosis Caused by Rapidly Corrected Hyponatremia. <i>Journal of Neuroimaging</i> , 2009, 19, 185-187.	2.0	17
32	White Matter Changes May Precede Gray Matter Loss in Elderly with Subjective Memory Impairment. <i>Dementia and Geriatric Cognitive Disorders</i> , 2016, 42, 227-235.	1.5	17
33	Normalization of cortical thickness measurements across different T1 magnetic resonance imaging protocols by novel W-Score standardization. <i>NeuroImage</i> , 2017, 159, 224-235.	4.2	17
34	Cerebellar Atrophy in Patients with Subcortical-Type Vascular Cognitive Impairment. <i>Cerebellum</i> , 2013, 12, 35-42.	2.5	16
35	Clinical Evaluation of 18F-PI-2620 as a Potent PET Radiotracer Imaging Tau Protein in Alzheimer Disease and Other Neurodegenerative Diseases Compared With 18F-THK-5351. <i>Clinical Nuclear Medicine</i> , 2020, 45, 841-847.	1.3	16
36	Cortical Thinning in Verbal, Visual, and Both Memory-predominant Mild Cognitive Impairment. <i>Alzheimer Disease and Associated Disorders</i> , 2011, 25, 242-249.	1.3	15

#	ARTICLE	IF	CITATIONS
37	A Consensus in Korea Regarding a Protocol to Reduce Preanalytical Sources of Variability in the Measurement of the Cerebrospinal Fluid Biomarkers of Alzheimer's Disease. Journal of Clinical		



#	ARTICLE	IF	CITATIONS
55	Amyloid Beta-Weighted Cortical Thickness: A New Imaging Biomarker in Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2015, 12, 563-571.	1.4	5
56	¹⁸ F-THK5351 PET Positivity and Longitudinal Changes in Cognitive Function in ¹² I-Amyloid-Negative Amnesic Mild Cognitive Impairment. <i>Yonsei Medical Journal</i> , 2022, 63, 259.	2.2	5
57	Teaching Neuro <i>Image</i> : Diverse MRI signal intensities with Wernicke encephalopathy. <i>Neurology</i> , 2008, 70, e48.	1.1	4
58	Medulla compression caused by vertebral artery dolichoectasia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 79, 222-222.	1.9	4
59	Human Herpes Virus 6 Encephalitis Following Bone Marrow Transplantation with Uncommon Magnetic Resonance Imaging Findings. <i>Dementia and Neurocognitive Disorders</i> , 2016, 15, 88.	1.4	4
60	Role of White Matter Abnormalities in the Relationship Between Microbleed Burden and Cognitive Impairment in Cerebral Amyloid Angiopathy. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 667-678.	2.6	3
61	[¹⁸ F]THK-5351 PET Patterns in Patients With Alzheimer's Disease and Negative Amyloid PET		

#	ARTICLE	IF	CITATIONS
73	P3-229: CLINICAL CHARACTERISTICS AND MRI FINDINGS IN PATIENTS WITH CAA. , 2014, 10, P714-P715.		0
74	P4-125: SCHELTENS' VISUAL RATING SCALE IN ALZHEIMER'S DEMENTIA: ARE WE AFFECTED BY THE DEGREE OF GENERALIZED CORTICAL ATROPHY WHILE RATING?. , 2014, 10, P831-P831.		0
75	P1-201: CEREBROVASCULAR ATHEROSCLEROSIS AND COGNITION IN PATIENTS WITH ALZHEIMER'S DISEASE. , 2014, 10, P377-P377.		0
76	P2-187: PATTERNS OF HIPPOCAMPAL SHAPE CHANGES IN PATIENTS WITH FRONTOTEMPORAL DEMENTIA. , 2014, 10, P539-P539.		0
77	P2-143: Prediction of Alzheimer's disease pathophysiology based on cortical thickness patterns. , 2015, 11, P541-P541.		0
78	P4-183: Regional Amyloid Burden and Lacunar Infarct in Pure Subcortical Vascular Cognitive Impairment. Alzheimer's and Dementia, 2016, 12, P1090.	0.8	0
79	P4-197: Clinical Implication of Amyloid β Accumulation in Occipital Lobes Using a [18F]Florbetaben PET. Alzheimer's and Dementia, 2016, 12, P1099.	0.8	0
80	O3-0206: Regional Comparison of Imaging Biomarkers in the Striatum Between Early Versus Late-Onset Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P284.	0.8	0
81	[P1-129]: PREDICTION MODEL OF TAU PROPAGATION IN AD SPECTRUM USING FUNCTIONAL NETWORK. Alzheimer's and Dementia, 2017, 13, P291.	0.8	0
82	[P2-361]: SURFACE-BASED ANALYSIS OF SUBCORTICAL STRUCTURES IN TAU AND AMYLOID PET IMAGING: AN ALZHEIMER'S DISEASE STUDY. Alzheimer's and Dementia, 2017, 13, P762.	0.8	0
83	[P2-406]: IN VIVO BRAAK STAGING OF AMNESTIC MCI USING ¹⁸ F-THK5351 PET IMAGING. Alzheimer's and Dementia, 2017, 13, P786.	0.8	0
84	[P2-424]: PROTECTIVE EFFECTS OF EDUCATION ON THK-5351 UPTAKES IN MILD COGNITIVE IMPAIRMENT WITH SUSPECTED NON-ALZHEIMER PATHOLOGY. Alzheimer's and Dementia, 2017, 13, P798.	0.8	0
85	[P3-319]: MILD COGNITIVE IMPAIRMENT CLASSIFICATION USING DEEP LEARNING. Alzheimer's and Dementia, 2017, 13, P1070.	0.8	0
86	[P3-337]: THK5351 UPTAKES IN EARLY AND LATE STAGES OF AMNESTIC MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P1082.	0.8	0
87	[P3-383]: REGIONAL CANONICAL ASSOCIATION OF AMYLOID β AND GLUCOSE METABOLISM SUGGESTIVE OF EARLY BRAIN DYSFUNCTIONS IN NORMAL ELDERLY WITH APOE ϵ 4 ALLELE. Alzheimer's and Dementia, 2017, 13, P1106.	0.8	0
88	[P4-046]: PARTIAL VOLUME SUSCEPTIBILITY OF TAU PET: REGIONWISE ASSESSMENT AND COMPARISON WITH AMYLOID PET. Alzheimer's and Dementia, 2017, 13, P1274.	0.8	0
89	[P1-132]: IMPROVEMENT OF CORTICAL THICKNESS COMPATIBILITY BETWEEN DIFFERENT MRI T1 PROTOCOLS BY WASSCORE STANDARDIZATION. Alzheimer's and Dementia, 2017, 13, P292.	0.8	0
90	[P4-253]: QUANTITATIVE ANALYSIS AND CORRELATION WITH COGNITIVE FUNCTION OF ¹⁸ F-THK-5351 PET IN SUBJECTIVE MEMORY IMPAIRMENT, MILD COGNITIVE IMPAIRMENT, AND ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P1377.	0.8	0

#	ARTICLE	IF	CITATIONS
91	[P1â€“454]: POSITIVE ASSOCIATION BETWEEN EDUCATION AND THKâ€“5351 UPTAKES IN PATIENTS WITH ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P460.	0.8	0
92	[O1â€“08â€“01]: PATTERNS OF REGIONAL TAU ACCUMULATION INDICATIVE OF THREE DIFFERENT TYPES OF ALZHEIMER'S DISEASE (AD): THK5351â€“PETâ€“BASED REPLICATION OF PATHOLOGYâ€“BASED AD CLASSIFICATION. Alzheimer's and Dementia, 2017, 13, P206.	0.8	0
93	P2â€“359: RELATION NETWORKS OF NEURODEGENERATION IN ALZHEIMER'S DISEASE SPECTRUM: TAU, AMYLOID, AND CORTICAL ATROPHY. Alzheimer's and Dementia, 2018, 14, P827.	0.8	0
94	P1â€“396: COGNITION AND NEUROFIBRILLARY DEGENERATION IN PATIENTS WITH AMYLOIDâ€“NEGATIVE MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P454.	0.8	0
95	P2â€“236: SLEEP CHANGES IN ALZHEIMER'S DISEASE SPECTRUM DISORDERS MEASURED BY A PORTABLE POLYSOMNOGRAPHY. Alzheimer's and Dementia, 2018, 14, P762.	0.8	0
96	P3â€“089: DATAâ€“DRIVEN PATHOLOGICAL POSITIVITY OF ALZHEIMER DISEASE: AN EXPLORATORY STUDY OF DYNAMIC BIOMARKER CAUSALITY. Alzheimer's and Dementia, 2018, 14, P1099.	0.8	0
97	P3â€“433: NEURAL SUBSTRATES OF COGNITIVE RESERVE IN THE ALZHEIMER'S DISEASE SPECTRUM. Alzheimer's and Dementia, 2018, 14, P1277.	0.8	0
98	Survival in Korean Patients with Frontotemporal Dementia Syndrome: Association with Behavioral Features and Parkinsonism. Journal of Clinical Medicine, 2022, 11, 2260.	2.4	0